Paradigm Biopharmaceuticals (ASX:PAR) YoY EBITDA Growth : -41.74% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Paradigm Biopharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -41.74%.

Paradigm Biopharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.16.

Paradigm Biopharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Paradigm Biopharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals YoY EBITDA Growth Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

YoY EBITDA Growth

Get a 7-Day Free Trial

6.76

15.94

-175.86

-1.88

-9.82

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial												-28.74	28.17	-2.68	-29.41	-41.74

Paradigm Biopharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Paradigm Biopharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

	YoY EBITDA Growth (A: Jun. 2023 )
=	(EBITDA per Share (A: Jun. 2023 )	-	EBITDA per Share (A: Jun. 2022 ))	/	\| EBITDA per Share (A: Jun. 2022 ) \|
=	(-0.179	-	-0.163)	/	\| -0.163 \|
=	-9.82 %

Paradigm Biopharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.163	-	-0.115)	/	\| -0.115 \|
=	-41.74 %

Paradigm Biopharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).